FDA
-
-
-
-
-
-
-
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
-
-
-
-
-
-
-
Amneal reports positive interim results for CREXONT in Parkinson's study
-
-
-
-
-
-
-
Amneal receives FDA approval for two denosumab biosimilar drugs
-
-
-
-
-
-
-
Amneal gets FDA approval for generic albuterol inhaler
-
-
-
-
-
-
-
Amneal receives tentative FDA approval for generic asthma inhaler
-
-
-
-
-
-
-
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
-
-
-
-
-
-
-
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
-
325,819 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

